Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus PROPRANOLOL HYDROCHLORIDE INTENSOL.
INDERIDE LA 120/50 vs PROPRANOLOL HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and reduces CNS sympathetic outflow.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
Initial: 40 mg orally twice daily; maintenance: 120-240 mg/day in 2-3 divided doses. Maximum: 640 mg/day. For hypertension, start 40 mg twice daily, increase gradually.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Terminal elimination half-life is 3–6 hours, but clinical effects (e.g., beta-blockade) persist longer due to prolonged receptor occupancy. Half-life may increase in hepatic impairment.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Primarily hepatic metabolism (>99%) with <1% excreted unchanged in urine. Metabolites are excreted renally. Fecal elimination is minimal.
Category C
Category C
Beta-Blocker/Diuretic Combination
Beta-Blocker